IL2 and cancer: A novel approach based on Vγ9Vδ2 T-cell stimulation using an agonistic BTN3A-specific monoclonal antibody alone or in combination with IL-2 is currently being evaluated in a phase 2 clinical trial in advanced-stage cancer patients (20, 21).